PRIALT ( ziconotide intrathecal infusion): US FDA label indications
US FDA labelNot medical advice
The product name above is taken from the label's own indications text; the source record has no brand or generic name field.
Indications and usage (label excerpt)
INDICATIONS AND USAGE PRIALT ( ziconotide intrathecal infusion) is indicated for the management of severe chronic pain in patients for whom intrathecal (IT) therapy is warranted, and who are intolerant of or refractory to other treatment, such as systemic analgesics, adjunctive therapies, or IT morphine.
Excerpts are shortened. Read the full label, and ask a pharmacist or prescriber about any medicine. Full label on DailyMed(opens in a new tab) For products sold in Canada, see the Health Canada Drug Product Database(opens in a new tab).
Trials whose interventions mention this drug
Canadian trials first. A match on the drug name does not mean the trial studied this specific product.
2 trials, recruiting first
| Phase | Countries | ||||
|---|---|---|---|---|---|
| Ziconotide for Non-cancer Pain by Intrathecal Administration NCT06541184 | Recruiting | France | ESTEVE Pharmaceuticals SAS | 2024-10-30 | |
| Prialt (Ziconotide) In Severe Chronic Pain NCT00047749 | Completed | Phase 3 | United States | Elan Pharmaceuticals | 2002-08 |
Source: openFDA drug label (US FDA), snapshot October 2026. Not a Health Canada Product Monograph.